在基于生物信息学分析的基础上,探索糖尿病心肌病中血管生成的关键点分子
Fengli Hu1,2, Ruixue Guo1,2, Yaxin Zhi1,2
1Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, China.
Frontiers in endocrinology
|May 2, 2025
概括
糖尿病心肌病症会损害心脏的微血管. 这项研究确定了Efnb2是将血管新生损伤与糖尿病心肌病联系起来的关键分子,这表明它是潜在的治疗标.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病心肌病症是一个重大的临床挑战,发病率高,后果严重.
- 对心脏微血管血管生成的损伤是糖尿病心肌病的发展和进展的关键因素.
- 目前用于糖尿病心肌病的治疗方法缺乏血管新生损伤的直接点.
研究的目的:
- 为了确定涉及糖尿病心肌病和血管生成损伤的关键分子.
- 为潜在的治疗干预提供见解,以糖尿病心肌病中的血管生成为目标.
主要方法:
- 来自糖尿病心肌病的动物和细胞模型的测序数据的分析.
- 不同表达的血管生成相关基因的功能和通路分析.
- 在糖尿病小鼠和高葡萄糖刺激的人静脉内皮细胞 (HUVECs) 中验证微血管血管生成.
- 西方斑点分析验证顶级候选基因.
主要成果:
- 确定了24个不同表达的血管生成相关基因,其中11个在人类和小鼠数据集中显示一致的趋势.
- 在糖尿病小鼠心脏中确认了微血管新生受损,在高葡萄糖刺激的HUVEC中减少了管道形成/迁移.
- 在高葡萄糖条件下,Efnb2表达显著增加,而Edn1和Lepr没有显著变化.
结论:
- 在糖尿病心肌病模型中选与血管生成相关的差异基因.
- 阐明了一种新的分子轴,将血管新生损伤与糖尿病心肌病联系起来.
- 强调Efnb2作为糖尿病心肌病的潜在治疗点.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis
5.0K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


